Hematological Malignancies

FIT TRIAL Conclusions after 7 years Follow-up

• 90 Y-Ibritumomab consolidation confers a durable PFS benefit for patients with advanced FL • 3-year PFS advantage for patients in the ITT population • At least a 6-year PFS advantage for patients with a CR/CRu after induction > 5-year advantage in time to next treatment • No unexpected toxicities emerging Annualized rate of secondary MDS/AML was 0.55% in the Zevalin arm